A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies


NCT Number:



Study Status:






The main purpose of this study is learn about the the safety and side effects of the study drug, RGX-104. RGX-104 is an experimental drug. This means that RGX-104 is not approved by the Food and Drug Administration (FDA). This is the first time RGX-104 will be given to humans.

Are you Eligible? (Inclusion Criteria)

  • Do you have a confirmed solid tumor?
  • Have you had treatment for your disease before? Or is there not a standard treatment available for your disease?
  • Does your cancer continue to grow? Can your cancer not be removed by surgery?
  • Are you 18 years of age or older?

Specialty Area(s)

Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Ovarian Cancer, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Melanoma, Pancreatic Cancer, Sarcomas (Bone and Soft Tissue), Stomach Cancer, Testicular Cancer, Thyroid Cancer, Immunotherapy

Principal Investigator

Profile Headshot
  • Co-Director, Hereditary Breast and Ovarian Cancer Program

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032